ABSTRACT
Protein synthesis is a cyclical process consisting of translation initiation, elongation, termination and ribosome recycling. The release factors SBDS and EFL1 (both mutated in the leukaemia predisposition disorder Shwachman-Diamond syndrome) license entry of nascent 60S ribosomal subunits into active translation by evicting the anti-association factor eIF6 from the 60S intersubunit face. Here, we show that in mammalian cells, eIF6 holds all free cytoplasmic 60S subunits in a translationally inactive state and that SBDS and EFL1 are the minimal components required to recycle these 60S subunits back into additional rounds of translation by evicting eIF6. Increasing the dose of eIF6 in mice in vivo impairs terminal erythropoiesis by sequestering post-termination 60S subunits in the cytoplasm, disrupting subunit joining and attenuating global protein synthesis. Our data reveal that ribosome maturation and recycling are dynamically coupled by a mechanism that is disrupted in an inherited leukaemia predisposition disorder.
INTRODUCTION
Every minute, a growing HeLa cell synthesises around 7500 ribosomal subunits which decode messenger RNA to make protein through the four successive steps of translation: initiation, elongation, termination and recycling. Removal of the highly conserved nucleolar shuttling factor eukaryotic initiation factor 6 (eIF6) from the intersubunit face of the nascent large 60S ribosomal subunit is essential to license its entry into translation1, because eIF6 sterically inhibits the large 60S ribosomal subunit from joining to the small 40S subunit to form an actively translating ribosome2,3. eIF6 is initially recruited to pre-60S ribosomal subunits in the nucleolus4. Following export of the pre-60S particles to the cytoplasm, the GTPase EFL1 (elongation factor-like 1) and its cofactor SBDS (Shwachman-Bodian-Diamond syndrome) evict eIF6 during the final step in maturation of the nascent 60S subunit5–11.
Disruptive variants in both SBDS12 and EFL113 cause the inherited leukaemia predisposition disorder Shwachman-Diamond syndrome (SDS)14. Missense variants in eIF6 can bypass the fitness defect of yeast cells lacking the SBDS orthologue Sdo1 by reducing eIF6 binding to the 60S subunit7. In addition, diverse somatic genetic events including point mutations, interstitial deletion and reciprocal chromosomal translocation rescue the germline ribosome defect in SBDS-deficient haematopoietic cells either by reducing eIF6 expression or by disrupting the interaction of eIF6 with the 60S subunit15,16. The observation that mutations in eIF6 can rescue the defects in ribosomal subunit joining and translation initiation observed in SBDS-deficient cells15 raises the possibility that SBDS and EFL1 may have a more general role in translation beyond their function in nascent 60S subunit maturation. Cryo-electron microscopy (cryo-EM) studies further support this hypothesis by revealing that eIF6 is bound to 60S ribosome quality control intermediates17,18, suggesting that there are some contexts in which eIF6 may rebind to mature 60S ribosomal subunits in vivo.
In eukaryotes, translation termination begins with the recognition of a stop codon in the A site of the 80S ribosome by the release factors eRF1 and GTP-bound eRF319. Peptide release is temporally coupled to splitting of the 80S ribosome into a free 60S and a 40S subunit bound to deacylated tRNA and mRNA by the essential ATP-binding cassette protein Rli1 (yeast)/ABCE1 (mammals)20,21. The deacylated tRNA is subsequently removed, promoting dissociation of the 40S subunit from the mRNA20,22. ABCE1 blocks 40S rebinding to the 60S subunit by sterically hindering the formation of an intersubunit bridge between the 60S protein uL14 and the 40S rRNA helix h4423. However, the possibility that eIF6 rebinding might similarly sequester post-termination recycled 60S subunits in a translationally inactive state has not been addressed. Dissociated 40S and 60S subunits may immediately re-engage in further rounds of translation initiation or alternatively, in conditions of stress, enter a reservoir of translationally inactive 80S ribosomes24–27, that can again be recycled in an ABCE1-dependent manner28. Interestingly, ribosome recycling becomes critical for ribosome homeostasis during erythroid differentiation, as the natural loss of ABCE1 limits ribosome availability and results in the accumulation of post-termination, unrecycled ribosomes in the 3’UTRs of mRNAs29.
Here, we test the hypothesis SBDS and EFL1 act as general eIF6 release factors to regulate post-termination 60S ribosomal subunit recycling. Using cryo-EM, we show that eIF6 binds to the majority of free cytoplasmic 60S subunits in mammals, thereby holding them in a translationally inactive state. We reveal that SBDS and EFL1 are the minimal components required to evict 60S-rebound eIF6 and recycle post-termination 60S subunits back into the actively translating pool. Consistent with the requirement for efficient ribosome recycling during erythropoiesis, graded overexpression of eIF6 in mice perturbs late steps in erythroid differentiation by sequestering free 60S subunits, blocking subunit joining and attenuating global translation. Our data support a wider role for SBDS and EFL1 as translational regulators that dynamically couple 60S subunit maturation with ribosome recycling through the release of rebound eIF6.
RESULTS
eIF6 holds free cytoplasmic 60S subunits in a translationally inactive state in vivo
We set out to test the hypothesis that eIF6 maintains free cytoplasmic 60S subunits in a translationally inactive state in primary haematopoietic cells in vivo. Immunoblotting of cell extracts purified from primary murine c-kit+ bone marrow cells revealed that around 14 % of the eIF6 protein co-migrated with free 60S ribosomal subunits, while the majority was distributed in the free fraction (Figure 1A). Single particle cryo-electron microscopy (cryo-EM) analysis of free 60S particles purified from primary murine c-kit+ bone marrow cells revealed that eIF6 is stably bound to the intersubunit face of at least 83% of cytoplasmic mature 60S subunits (Figure 1B).
At an overall resolution of 3.1 Å, our cryo-EM reconstructions allowed us to build and refine atomic models of murine eIF6 bound to the 60S ribosomal subunit (Figure 1C and Supplementary Figure 1). Conserved from prokaryotes to human, eIF6 is a member of the pentein protein superfamily with five-fold pseudosymmetry30. Consistent with previous structures from yeast3, Tetrahymena31 and human cells15, murine eIF6 sterically inhibits 40S ribosomal subunit joining by binding to a conserved site on the intersubunit face of the 60S subunit involving the C terminus of uL1432, the sarcin-ricin loop (SRL), uL3 (residues 58–71) and the N terminus of eL24 (Figure 1D). We conclude that in primary murine haematopoietic cells, eIF6 holds all free 60S ribosomal subunits in a translationally inactive state by binding to the 60S intersubunit face. These data support the hypothesis that eIF6 must be released from the 60S ribosomal subunit to allow 80S ribosome assembly1. However, we were unable to discriminate nascent 60S-eIF6 complexes versus eIF6 rebound to mature 60S subunits.
Endogenous eIF6 can rebind mature cytoplasmic 60S subunits
The ribosome quality control (RQC) pathway recognises and rescues stalled translation complexes. Following ribosome dissociation, components of the RQC complex remain bound to the 60S subunit together with eIF617,33. Taken together with the finding that eIF6 is bound to virtually all mature cytoplasmic 60S ribosomal subunits, we hypothesised that during canonical translation termination (and RQC), eIF6 might rebind to mature 60S particles and require dynamic recycling by SBDS and the GTPase EFL1.
To support this hypothesis, we first tested the ability of eIF6 to rebind mature 60S particles that had been dissociated from 80S couples. Using immunoblotting, we examined the distribution of endogenous eIF6 following sucrose gradient fractionation of cell extracts prepared from c-kit+ murine bone marrow cells in 80S dissociating (2 mM Mg, 500 mM KCl) conditions. In contrast to non-dissociating conditions where eIF6 predominantly migrates in the free fraction (Figure 1A), eIF6 comigrated almost entirely with the 60S subunit (Figure 2A). Consistent with previous work1, we conclude that endogenous eIF6 can rebind mature cytoplasmic 60S subunits in mammalian cells.
SBDS and EFL1 are sufficient to release eIF6 rebound to 60S subunits
We next examined whether human SBDS, EFL1 and GTP are sufficient to promote the release of eIF6 rebound to mature cytoplasmic 60S subunits. We biochemically reconstituted an ex vivo assay that coupled eIF6 release from 60S subunits to their reassembly into 80S ribosomes by adding recombinant human SBDS and EFL1 to eIF6-loaded 60S subunits isolated from c-kit+ bone marrow cells. A schematic overview of the assay is shown in Figure 2B. As shown in the representative experiment in Figure 2C, compared with GTP alone (left panel), the addition of SBDS, EFL1 and GTP (right panel) to eIF6-loaded 60S subunits promoted redistribution of eIF6 into the free fraction of the sucrose gradient as detected by immunoblotting, with a concomitant 1.8-fold increase in 80S ribosome reassembly. We conclude that in the presence of GTP, SBDS and EFL1 are sufficient to release eIF6 that has rebound to mature 60S particles. These data provide biochemical support for the hypothesis that SBDS and EFL1 function as general release factors with dual roles in nascent 60S subunit maturation and in ribosome recycling.
Genetic interactions between SBDS, EFL1 and eIF6
We reasoned that if eIF6 dynamically rebinds to post-termination 60S ribosomal subunits, increasing the dose of eIF6 in vivo would titrate out free 60S subunits to impair ribosomal subunit joining, reduce global protein synthesis and induce growth defect. Consistent with this hypothesis, ubiquitous overexpression of wild type eIF6 (but not eIF6 missense mutants identified in SDS haematopoietic cells that map to the interface with the 60S subunit) induces late larval lethality in Drosophila15. Furthermore, overexpression of SDS patient-derived eIF6 missense mutations can fully rescue the lethality of Sbds-deficient flies15.
To further test the in vivo genetic interactions between Sbds and eIF6, we depleted Sbds using RNAi15, allowing flies to develop to adult stage albeit more slowly compared with wild type controls (Figure 3A). At 29 °C, 5.4 % of Sbds-depleted flies develop from pupae to adults (n = 269, 3 replicates); at 25 °C, 55.5 % of pupae develop to adults (n = 276, 2 replicates). RNAi-mediated depletion of Sbds enhanced the growth defect induced by ubiquitous overexpression of eIF6, causing lethality at the early larval stage (Figure 3A). In the developing ommatidia, selective eIF6 overexpression induced a small, rough eye phenotype (Supplementary Figure 2) that was enhanced either by doubling the dose of eIF6 or by depleting Sbds or Efl1 by RNAi (Figure 3B, Supplementary Figure 2). Selective overexpression of eIF6 in the Drosophila wing disc reduced global protein synthesis as measured by O-propargyl-puromycin (OP-puro) incorporation (Figure 3C). These genetic data support the hypothesis that SBDS and EFL1 function in mobilizing eIF6 that has rebound to cytoplasmic 60S ribosomal subunits in vivo.
eIF6 dose-dependent inhibition of ribosomal subunit joining in vivo
We set out to further validate the hypothesis that eIF6 dynamically rebinds to post-termination cytoplasmic 60S ribosomal subunits by engineering a transgenic eIF6 mouse strain that permits doxycycline (Dox, tetracycline analogue)-inducible and graded overexpression of the human EIF6 transgene by constitutively expressing the M2-reverse tetracycline transactivator (M2-rtTA) at the Rosa26 promoter34 (Figures 4A, 4B). M2-rtTA is a mutant of rtTA that has increased stability, reduced background expression and improved inducibility in the presence of Dox35. This transgenic mouse strain exhibits widespread constitutive expression of M2-rtTA, allowing for Dox-inducible transactivation of the human EIF6 cDNA. We adjusted the level of eIF6 overexpression by breeding animals that were heterozygous or homozygous for the M2-rtTA at the Rosa26 locus and carried one or two copies of the human EIF6 transgene at the Col1a1 locus (Figure 4B). To evaluate the level of EIF6 transgene expression, we treated cultured c-Kit+ bone marrow cells with Dox and performed quantitative real-time PCR to measure EIF6 mRNA. We designed two sets of primers to distinguish endogenous mouse Eif6 mRNA from total (endogenous + transgene) EIF6 mRNA to verify the transgene copy number–dependent increase in total EIF6 expression (Figure 4C). The increase in EIF6 mRNA led to a significant increase in the level of eIF6 protein expression compared with control animals (Figure 4D).
Next, we assessed the impact of increasing doses of eIF6 on ribosome assembly in vivo by fractionating cell extracts in the presence of cycloheximide from Dox-treated c-Kit+ bone marrow cells by sucrose gradient sedimentation. Depending on the level of overexpression, the increased dose of eIF6 promoted a reduction in the 80S:60S ratio, consistent with a subunit-joining defect (Figure 4E). Parallel experiments using high salt buffer to specifically dissociate inactive mRNA-free 80S monosomes36, further highlighted the eIF6 dose-dependent reduction in actively translating 80S ribosomes (Figure 4F). Finally, by using a magnesium-free buffer system, we observed that the ratio of 60S to 40S subunits was preserved with an intermediate dose of eIF6 (Figure 4G). Although higher eIF6 overexpression resulted in a relative decrease in 60S subunits (Figure 4H), this is likely to be a secondary consequence of the profound reduction in global protein synthesis. We conclude that graded eIF6 overexpression induces a dose-dependent ribosomal subunit joining defect in vivo. Importantly, the observed ribosomal subunit joining defect upon eIF6 overexpression closely mimics the subunit joining defect caused by eIF6 retention on the 60S subunit that is observed in Sbds- or Efl1 deficient mice or patient-derived lymphoblasts8,9,13,37. Taken together with our genetic data in Drosophila, we propose that the most logical interpretation of these findings is that eIF6 rebinds to post-termination recycling 60S subunits from which it is dynamically recycled by SBDS and EFL1. These data support the hypothesis that SBDS and EFL1 translationally activate nascent 60S subunits and in addition act as general eIF6 release factors that dynamically recycle eIF6-bound post-termination 60S subunits back into additional rounds of translation.
Terminal erythroid differentiation is sensitive to eIF6 dosage
We reasoned that during mammalian haematopoiesis, the erythroid lineage might be particularly sensitive to an increased dose of eIF6 and aberrant ribosome homeostasis due to the increased dependence of terminal erythroid differentiation on ribosome recycling as a consequence of natural loss of the ribosome recycling factor ABCE129. To test this hypothesis, we induced eIF6 overexpression in vivo in transgenic mice.
Detailed analysis of mice carrying two copies of the M2-rtTA transgene and either one or two copies of the EIF6 transgene was precluded because of the rapid weight loss induced in these animals. By contrast, mice that were heterozygous for both transgenes (M2-rtTA/+; EIF6/+, herein called eIF6hi mice) did not lose weight acutely in response to Dox administration (Supplementary Figure 3). We therefore restricted our analysis to eIF6hi mice.
Immature (lineage-, Sca-1+, c-Kit+; LSK), myeloid (preGM/GMP) and erythroid (preCFU-E/CFU-E) haematopoietic progenitor cells isolated from Dox-treated eIF6hi mice showed a 2-4 fold increase in EIF6 mRNA (Supplementary Figure 4A), while sucrose gradient sedimentation analysis of extracts from cultured c-Kit+ bone marrow cells showed accumulation of free 40S and 60S subunits compared with control (Supplementary Figure 4B). Immunoblotting revealed a robust increase in eIF6 protein across the gradient (Supplementary Figure 4C). Compared with controls, the overexpressed eIF6 protein predominantly accumulated in the cytoplasm of freshly isolated bone marrow cells in eIF6hi mice (Supplementary Figure 4D).
After two weeks of Dox administration, eIF6hi mice developed persistent macrocytic anaemia with a significant reduction in the reticulocyte count compared with controls (Figure 5A and 5B). While the platelet count increased, the total white blood cell count was unaffected (Supplementary Figure 5). Histological examination of the bone marrow revealed erythroid hyperplasia in eIF6hi mice, with an increased frequency of erythroid precursors compared with controls (Supplementary Figure 6A). In addition, the spleen was enlarged in eIF6hi mice (Supplementary Figure 6B), due to marked expansion of erythroid precursors (Supplementary Figure 6C).
To further characterise haematopoiesis in the eIF6hi mice, we analysed bone marrow cells by flow cytometry38,39, using the gating strategy shown schematically in Supplementary Figure 7. The eIF6hi mice showed no significant differences in overall bone marrow cellularity relative to controls (Supplementary Figure 8A). Although the frequency of myeloid and multipotent progenitors (preGM and MPPs) decreased, the frequency of erythroid progenitors (preCFU-E and CFU-E) (Supplementary Figure 8B) and precursor cells (Figure 5C-E) was significantly increased. A similar increase in the frequency of erythroid precursors was detected by flow cytometry in the spleen (Supplementary Figure 8C). Within the bone marrow, we identified an abnormal population of orthochromatic erythroblast-like cells (CD44lo FSClo) containing a highly condensed nucleus and low cytoplasmic volume (Figure 5C-E).
We hypothesised that an increased dose of eIF6 might impair erythroblast enucleation during the terminal steps of erythroid differentiation, promoting the accumulation of orthochromatic erythroblast-like cells, but reducing the numbers of reticulocytes. To test this, we applied Amnis ImageStream technology40,41 to visualise active nuclear extrusion by bone marrow erythroblasts, dividing the process into early, intermediate and late stages (Figure 5F and Supplementary Figure 9). Compared with controls, in Dox-treated eIF6hi mice we classified more erythroblasts in the early or intermediate stages of enucleation compared with late steps (Figure 5G). We conclude that an increased dose of eIF6 impairs terminal enucleation of orthochromatic erythroblasts in vivo.
We next set out to determine whether the eIF6-dependent erythroid differentiation defect was intrinsic to eIF6hi haematopoietic cells. Consistent with this hypothesis, ex vivo differentiation of CFU-Es/proerythroblasts isolated from Dox-treated eIF6hi mice recapitulated the eIF6-dependent defect in terminal erythropoiesis (Supplementary Figure 8D). Furthermore, non-competitive transplantation of bone marrow cells from eIF6hi mice into lethally irradiated wild type congenic recipients also recapitulated the eIF6 dose-dependent haematopoietic abnormalities (Supplementary Figure 10). Taken together, our data indicate that the terminal erythroid maturation defects are intrinsic to eIF6hi haematopoietic cells.
Attenuated protein synthesis impairs terminal erythroblast enucleation
We hypothesised that increasing the dose of eIF6 would alter ribosome homeostasis during erythropoiesis by shifting the equilibrium towards ribosomal subunit dissociation, thereby attenuating protein synthesis. To test this, we quantified the rate of global protein synthesis in erythroid cells in vivo by measuring OP-puro incorporation. Indeed, compared with controls, we observed a significant decrease in OP-puro incorporation in late poly- and orthochromatic erythroid precursors from Dox-treated eIF6hi mice (Figure 6A). These data demonstrate that eIF6 overexpression impairs terminal erythroid differentiation by a mechanism that directly or indirectly attenuates protein synthesis.
We reasoned that the reduced rate of protein synthesis in late erythroblasts from Dox-treated eIF6hi mice likely reflects altered ribosome homeostasis as a consequence of an increase in the relative ratio of eIF6 to ribosomes during terminal erythroid differentiation. To test this hypothesis, we sorted identical numbers of erythroid progenitor and precursor cells from Dox-treated mice and performed immunoblotting to visualise eIF6 and Rps19 (as a marker for cellular ribosome levels). In control mice, the levels of eIF6 and Rps19 peaked in early erythroblasts and progressively declined during terminal erythroid differentiation (Figure 6B). By contrast, erythroblasts in Dox-induced eIF6hi mice exhibited sustained high levels of eIF6 (Figure 6B). The relative intensity of thiazole orange staining (correlating with cellular ribosomal RNA content) of freshly isolated erythroblasts was consistent with a progressive decline in cellular ribosome levels during terminal erythroid maturation (Figure 6C). Taken together, these results indicate that an increased dose of eIF6 relative to ribosomal subunits is sustained in the eIF6hi mice throughout erythropoiesis. Erythroid differentiation is likely susceptible to increased eIF6 dosage due to the combined shutdown in new ribosome synthesis in early erythroblasts42 together with the loss of effective ribosome recycling through natural loss of the ribosome recycling factor ABCE1 during terminal differentiation29. We propose that the increased dose of eIF6 titrates out recycled post-termination 60S subunits during late erythroid differentiation to push the equilibrium in favour of ribosomal subunit dissociation, impaired translation initiation and attenuated protein synthesis. Finally, consistent with the impact of eIF6 overexpression on terminal erythroid differentiation, inhibition of protein synthesis with the translational elongation inhibitor homoharringtonine in prospectively isolated wild-type orthochromatic erythroblasts recapitulated the erythroblast enucleation defect observed in eIF6hi mice (Figure 6D).
DISCUSSION
In this study, we have identified a critical role in the regulation of translation initiation for the SBDS and EFL1 proteins through their role as general eIF6 release factors. Using cryo-EM, we provide direct evidence that eIF6 holds virtually all free cytoplasmic 60S subunits in mammalian cells in a translationally inactive state and show that SBDS and EFL1 are the minimal components required to recycle eIF6 that has rebound to post-termination 60S subunits. Depletion of Sbds or Efl1 exacerbates the growth defects caused by eIF6 overexpression in Drosophila in vivo, while eIF6 overexpression in mice causes a dose-dependent defect in ribosomal subunit joining by rebinding and titrating out post-termination 60S subunits from active translation. The observation that inactive 80S monosomes accumulate in eIF6 haploinsufficient mice43 also supports the hypothesis that eIF6 prevents the formation of inactive 80S monosomes by binding to post-termination 60S subunits. Taken together, our data support a role for SBDS and EFL1 in regulating ribosome homeostasis by coupling the final step in cytoplasmic 60S subunit maturation with post-termination 60S ribosomal subunit recycling through their role as general eIF6 release factors (Figure 7).
Translation of mRNA occurs in four steps: initiation, elongation, termination and ribosome recycling. During the normal translation cycle, once the ribosome reaches the stop codon of the mRNA, eRF1 and eRF3 recognise the stop codon and trigger hydrolysis of the nascent chain. Upon dissociation of eRF3, 80S ribosomes are recycled by recruitment of the ATPase ABCE1 to regenerate free 40S and 60S subunits20. This process maintains ribosome homeostasis by promoting additional rounds of translation initiation. Following 80S ribosome dissociation, the free 60S subunit may re-enter a new round of translation by binding a 48S pre-initiation complex to form an elongation competent 80S. Alternatively, it may bind an empty 40S subunit to form a vacant mRNA-free 80S monosome. A third possibility is that post-termination 60S subunits bind eIF6 to maintain the cytoplasmic pool of free ribosomal subunits in a translationally inactive state.
This begs the question of how translationally inactive eIF6-bound 60S subunits are recycled back into active translation. Genetically, depletion of SBDS and EFL1 reduces global protein synthesis due to the defect in ribosomal subunit joining caused by eIF6 retention on the intersubunit face of the 60S subunit7,13,15. While SBDS and EFL1 are known to release eIF6 during the final cytoplasmic step in nascent 60S maturation, the marked reduction in protein synthesis in SBDS and EFL1-deficient cells suggested to us that these factors may have a broader role as general release factors that liberate rebound eIF6 in a number of different contexts such as during post-termination ribosome recycling.
Although eIF6 was shown to bind to free 60S subunits by immunoblotting of mammalian cell extracts fractionated by sucrose gradient sedimentation1, the stoichiometry of this interaction in vivo remained unclear. In this study, we show that increasing the dose of eIF6 in vivo alters ribosome homeostasis by sequestering all free post-termination cytoplasmic 60S subunits, impairing ribosomal subunit joining and reducing 80S assembly. The subunit joining defect induced by eIF6 overexpression mimics the consequences of SBDS or EFL1 deficiency in SDS patient cells, Dictyostelium, mice and zebrafish8,9,13,37 and is exacerbated by concomitant depletion of either SBDS or EFL1. Our data therefore suggest that increasing the dose of eIF6 alters ribosome homeostasis by exceeding the capacity of endogenous SBDS and EFL1 to evict eIF6 from dynamically recycling 60S subunits.
Our findings suggest that the inability to dynamically upregulate recycling of post-termination ribosomes back into active translation at key time points during development may be a critical facet of SDS pathogenesis. This is exemplified by the defect in erythroid differentiation we observed in mice expressing an increased dosage of eIF6. Our model provides a more satisfactory explanation of why diverse mosaic somatic genetic events, including point mutations, interstitial deletion and reciprocal chromosomal translocation involving EIF6 may confer a selective advantage in SBDS-deficient haematopoietic cells15 by disrupting the expression of eIF6 or its interaction with cytoplasmic (but not nuclear) 60S subunits, thus still preserving ribosome biogenesis. Indeed, SDS-related somatic EIF6 missense mutations that reduce eIF6 dosage or binding to cytoplasmic 60S subunits suppress the ribosome assembly and protein synthesis defects across multiple SBDS-deficient species including yeast, Dictyostelium, Drosophila and human cells15. Taken together, these genetic and biochemical data support a major role for SBDS and EFL1 in regulating cytoplasmic ribosome homeostasis and translational control.
As our transgenic mice overexpressing eIF6 recapitulate the defect in ribosome assembly observed in SDS, this model may provide a tool to further dissect SDS pathogenesis. Similar to germline depletion of Sbds or Efl1 in mice13,37,44,45, high doses of eIF6 are not systemically tolerated. However, future studies combining the EIF6 transgene with tissue-specific tetracycline transactivator mouse strains will bypass this limitation, harnessing the full potential of this model. Finally, our inducible eIF6 transgenic mouse model may find utility in the development of therapeutic strategies to restore cytoplasmic ribosome homeostasis in SDS by modulating the rebinding of eIF6 to cytoplasmic 60S subunits.
MATERIALS AND METHODS
Generation of transgenic eIF6 mouse strain
Gibson assembly was used to clone a full-length human EIF6 cDNA containing Kozak sequence (5’-ATCACG-3’) into the EcoRI site of pBS31 vector, which was in turn used to target the KH2 embryonic stem (ES) cell line34. The engineered ES cells were injected into E3.5 C57BL/6 blastocysts to generate chimeric mice. Mice were backcrossed into the C57BL/6 background for at least three generations. PCR was used to genotype the Rosa26 locus (5’-AAAGTCGCTCTGAGTTGTTAT-3’; 5’-GCGAAGAGTTTGTCCTCAACC-3’; 5’-GGAGCGGGAGAAATGGATATG-3’; WT product: 600 bp; Insert product: 300 bp) and the Col1a1 locus (5’-TCCCTCACTTCTCATCCAGATATT-3’; 5’-AGTCTTGGATACTCCGTGACCATA-3’; 5’-GGACAGGATAAGTATGACATCATCAA-3’; WT product: 1092 bp; Insert product: 455 bp). The EIF6 transgene was induced in vivo by administering Dox in the food (ssniff-Spezialdiäten GmbH; 2000 mg/kg). Mice were maintained in specific pathogen-free conditions and all procedures were performed according to the United Kingdom Home Office regulations. All experiments were performed using adult (8-12 weeks old) female and male mice with littermate controls.
Peripheral blood analysis
Peripheral blood was collected from the tail vein into Microvette® 500 K3E tubes (Sarstedt) and cellularity analysed using a Woodley ABC blood counter.
Histopathology
Organs for histopathological analysis were fixed in 4 % formaldehyde (Genta Medical, UK) followed by paraffin embedding and sectioning. Sections were stained with Hematoxylin-Eosin (Merck) for microscopic examination. FACS-purified erythroid precursors were transferred onto slides using a cytospin centrifuge and stained with May-Grünwald and Giemsa solutions (Merck). Morphological examination was performed using AxioImager Z2 Upright Wide-field Microscope (Zeiss).
Flow cytometry
We isolated bone marrow cells by crushing hips, femurs and tibias in PBS (Thermo Fisher Scientific) supplemented with foetal calf serum (FCS; 2 %; Thermo Fisher Scientific) and EDTA (2 mM; Thermo Fisher Scientific). Isolated cells were filtered through a 70 µm cell strainer (Thermo Fisher Scientific). Antibody labelling was performed in PBS (+2 % FCS) for 30 min on ice. Antibodies are listed in the Supplementary Table 1. Erythrocytes were removed from peripheral blood by Dextran sedimentation (2 % in PBS; Merck) and ACK lysis buffer (Thermo Fisher Scientific) before antibody labelling. Experiments were performed using FACSARIA III cell sorter (BD Biosciences) and LSRFortessa flow cytometer (BD Biosciences), and analysed using FlowJo software (Tree Star, v10.1r7).
Imaging flow cytometry
Sample preparation was performed as previously described41. Briefly, 10 × 106 unfractionated bone marrow cells were fixed using formaldehyde (4 %; Alfa Aesar) for 15 min at room temperature. Following two washes with PBS, the cell pellet was cooled on ice for 15 min, and permeabilised using ice-cold acetone (a cycle of 50%-100%-50%). Following a wash with PBS (+2 % FCS), cells were stained for surface markers. Finally, 10 × 106 cells were resuspended in 100 µL PBS supplemented with DRAQ5 (2.5 µM; BioLegend), with acquisition performed on an ImageStream®X Mark II Imaging Flow Cytometer (Merck) using a 40 × objective lens. Approximately 50 000 events per sample were collected, and data analysis was performed using the associated Image Data Exploration and Analysis software (IDEAS; v.6.2; Merck).
Cell isolation and culture
c-Kit+ bone marrow cells were enriched using CD117 MicroBeads and MACS separation columns (Miltenyi Biotec), and cultured in OptiMEM I reduced Serum Media (Thermo Fisher Scientific), supplemented with FCS (10 %), penicillin/streptomycin (P/S, Life Technologies), β-mercaptoethanol (50 µM; Thermo Fisher Scientific), murine stem cell factor (mSCF; 100 ng/mL, PeproTech), murine interleukin 3 (mIL-3; 10 ng/mL, PeproTech) and murine granulocyte-colony stimulating factor (mG-CSF; 10 ng/mL, PeproTech) ± Dox (1 µg/mL; Merck). Biotinylated antibodies and Anti-Biotin MicroBeads (Miltenyi) were used for lineage depletion. In vitro erythroid culture was performed as previously described46. Briefly, 1-2.5 × 105 CFU-E/proerythroblasts isolated from Dox-treated mice were seeded on fibronectin-coated (2 µg/mL; Merck) 48-well plates in Iscove’s modified Dulbecco’s medium (IMDM; Thermo Fisher Scientific) containing FCS (15 %), bovine serum albumin (BSA; 1 %; Stem Cell Technologies), mSCF (10 ng/mL), recombinant human erythropoietin (10 U/mL; Cell Signaling Technology), human recombinant insulin (100 µg/mL; Merck), recombinant human insulin-like growth factor 1 (hIGF1; 100 ng/mL; Thermo Fisher Scientific), holo-transferrin (200 µg/mL; Merck), L-glutamine (2 mM; Merck), β-mercaptoethanol (50 µM) and P/S. The following day, culture media was replaced with differentiation media consisting of IMDM, FCS (20 %), β-mercaptoethanol (50 µM), P/S and L-glutamine (2 mM). Homoharringtonine-supplemented differentiation media was used to assess the enucleation of prospectively purified orthochromatic erythroblasts.
Transplantation assays
Non-competitive transplantations were performed by injecting 5 × 106 freshly isolated unfractionated bone marrow cells in 250 µL PBS (+2 % FCS) into the tail vein of lethally irradiated (2x 500 cGY) congenic (CD45.1) wild-type recipients. Reconstituted mice were allowed to recover for two weeks before Dox administration.
Protein synthesis rate measurement
O-propargyl-puromycin (OP-puro) labelling experiments were performed as previously described47. Briefly, OP-puro (50 mg/kg in 200 µL PBS; Jena Bioscience) was injected intraperitoneally and bone marrow cells were isolated after 1 hr. 3 × 106 cells were fixed with formaldehyde (4 %) for 15 min at room temperature. Following two washes with PBS (+2 % FCS), cells were stained with antibodies against cell surface markers. Stained cells were permeabilised using PBS supplemented with saponin (0.1 %; Merck) and FCS (2 %). The Click reaction was performed using the Click-iT™ Plus OPP Alexa Fluor™ 488 Protein Synthesis Assay Kit according to manufacturer’s instructions (Thermo Fisher Scientific).
Polysome profiling experiments
Equal numbers of c-Kit+ bone marrow cells were expanded in the presence of doxycycline for 24 hours and treated with cycloheximide (CHX; 100 µg/mL; Merck) for 8 min at 37 °C before harvesting by centrifugation. Cells were washed twice with ice-cold PBS supplemented with CHX (100 µg/mL) and lysed for 30 min on ice in ‘standard’ lysis buffer (20 mM Hepes pH 7.5, 50 mM KCl, 10 mM Mg(CH3COO)2, 100 µg/mL CHX, cOmplete™ EDTA-free Protease Inhibitor Cocktail (Merck), RNaseOUT recombinant ribonuclease inhibitor (200 U/mL; Thermo Fisher Scientific) and IGEPAL® CA-630 (0.5 %; Merck), Dithiothreitol (DTT; 2 mM; Merck). The lysate was cleared by centrifugation (18 000 g for 8 min at 4 °C), and loaded onto a 5-45 % (w/v) sucrose gradient (prepared in 20 mM Hepes pH 7.5, 50 mM KCl, 10 mM Mg(CH3COO)2, 100 µg/mL CHX and cOmplete™ EDTA-free Protease Inhibitor Cocktail) prepared in a polypropylene centrifuge tube (14 × 95 mm; Beckman Coulter). A Gradient Master (Biocomp) was used to prepare the sucrose gradients. After centrifugation (285, 000 g for 2 h at 4 °C using a Beckman SW40Ti rotor), polysome profiles were recorded using an Äktaprime plus chromatography system (GE Healthcare). Proteins were precipitated with trichloroacetic acid (25 % (vol/vol); 15 min on ice). Following centrifugation at 18 000 g for 5 min at 4 °C, protein precipitates were washed with ice-cold acetone. After drying at room temperature, protein pellets were resuspended in 1x NuPAGE LDS Sample Buffer (Thermo Fisher Scientific). Vacant 80S monosomes were dissociated in 20 mM Hepes pH 7.5, 200 mM KCl, 10 mM Mg(CH3COO)2, 100 µg/mL CHX, cOmplete™ EDTA-free Protease Inhibitor Cocktail (Merck), 200 U/mL RNaseOUT, 0.5 % IGEPAL® CA-630 and 2 mM DTT.
Purification of recombinant SBDS and EFL1 proteins
SBDS and EFL1 proteins were purified as previously described13.
eIF6 release assay
Preparation of mature 80S ribosomes
Expanded mouse c-Kit+ bone marrow cells were lysed in ‘standard’ lysis buffer (20 mM Hepes pH 7.5, 50 mM KCl, 10 mM Mg(CH3COO)2, supplemented with cOmplete™ EDTA-free Protease Inhibitor Cocktail, 200 U/mL RNaseOUT inhibitor, 0.5 % IGEPAL® CA-630 and 2 mM DTT). A total of 150 A260 units of lysate was loaded on six sucrose gradients, and fractions corresponding to 80S monosomes were collected and further concentrated by centrifuging 30 min at 80000 g in a Beckman MLA-80 rotor fitted in an Optima MAX-XP ultracentrifuge. The sedimented 80S particles were resuspended in ‘standard’ buffer and aliquots stored at -80 °C.
Preparation of exogenous eIF6
c-Kit+ bone marrow cells isolated from transgenic eIF6 mice (genotype [M2-rtTA/M2-rtTA][EIF6/+]) were expanded and treated with doxycycline for 24 h to induce eIF6 overexpression. Cells were then harvested and lysed in ‘dissociation’ lysis buffer (20 mM Hepes pH 7.5, 500 mM KCl, 2 mM Mg(CH3COO)2 supplemented with 100 µg/mL CHX, cOmplete™ EDTA-free Protease Inhibitor Cocktail, 200 U/mL RNaseOUT inhibitor, 0.5 % IGEPAL® CA-630 and 2 mM DTT). A total of 29 A260 units of lysate was run on a single sucrose gradient, and the free fraction, which contains the vast majority of cellular eIF6 but is devoid of ribosomes, was collected and aliquots stored at -80 °C.
In vitro eIF6 release assay
In the first part of the assay, 10 uL (1.25 A260 units) of mature 80S particles were mixed with 100 uL of exogenous eIF6 in ‘dissociation’ buffer. The reaction mix was then incubated at 37 °C for 15 min both to promote the dissociation of the mature 80S particles into 40S and 60S subunits, and to allow the binding of the exogenous eIF6 to 60S subunits. The amount of eIF6 supplied was optimised empirically to be in slight excess over 60S subunits, thus saturating the available 60S subunits without a significant accumulation in the free fraction. In the second part of the protocol, the reaction mix was diluted with 500 uL of prewarmed KCl-free buffer (20 mM Hepes pH 7.5, 10 mM Mg(CH3COO)2), and incubated at 37 °C for 5 min to allow reassembly of 80S particles. Since the joining of 40S and 60S subunits into 80S particles is proportional to the release of eIF6 from 60S subunits, this experimental strategy allows the assessment of eIF6 release based on quantification of 80S to 60S ratio. The reaction mix was split equally into two tubes that were supplied either with 1 mM GTP or 1 mM GTP + 1250 nM SBDS + 600 nM EFL1. Following 1 h incubation at 25 °C, the reaction mixes were cooled down on ice, and loaded on sucrose gradients prepared in ‘standard’ buffer conditions.
Electron cryo-microscopy sample preparation and data collection
c-Kit+ bone marrow cells were isolated from control mice that do not harbour EIF6 transgene, and expanded keeping cell concentration below one million cells per mL. CHX-treated cells were lysed in ’standard’ lysis buffer as described in ’Polysome profiling experiments’. Following sucrose gradient sedimentation, 60S subunits from multiple gradients were pooled, sedimented by centrifugation (45 min at 80000 g in an MLA-80 rotor), resuspended in 20 mM HEPES pH 7.5, 50 mM KCl, 5 mM Mg(CH3COO)2 at a concentration of 100 mM, and stored at -80 °C. 60S ribosomal subunits were thawed on ice and centrifuged in a benchtop centrifuge for 10 minutes at 20000 g and the supernatant was carefully recovered. EM grids were prepared by depositing 3 µl of 60S subunits at 100 nM to freshly glow-discharged Quantifoil R 1.2/1.3 holey carbon grids (PELCO easyGlow). Grids were then blotted with a Vitrobot Mark IV (FEI company) using the following parameters: blot time 1 s, blot force -7, wait time 10 s, no drain time. Blotted grids were finally vitrified in liquid ethane and stored in liquid nitrogen. Grids were screened on a Tecnai T12 microscope (FEI Company) and data acquisition performed under low-dose conditions on a Titan Krios microscope (FEI Company) operated at 300 kV over 24 h. The dataset was recorded on a Falcon III detector (FEI Company) at a nominal magnification of 75,000x (effective pixel size of 1.10 Å on the object scale) with a defocus range of −0.8 to −3.2 µm and a total dose of ∼77 e−/Å2 accumulated over 2 s exposures in 38 fractions. The acquisition of 3024 movies was performed semi-automatically using EPU software (FEI Company).
Electron cryo-microscopy data processing
Data processing was handled within the RELION software package48–50. Movies were first corrected for motion using Motioncor251 and CTF was estimated by CTFFIND452. Particles were then picked using the Laplacian-of-Gaussian (LoG) filter, extracted and 2D classified in RELION. 3D classification was then performed on selected 2D classes to further discard non-ribosomal and contaminating 80S particles. The 60S ribosomal subunit-containing class was selected for 3D auto-refinement to generate a consensus map. Masking and auto-sharpening was done through post-processing in RELION to obtain the final high-resolution map.
To quantify the proportion of eIF6-bound ribosomal particles, we made use of a combination of particle subtraction and 3D masked classifications in RELION (Figure 1B). We first focused on the L1-stalk to sort particles relative to their maturation state. We generated a mask around the L1-stalk and the tRNA E-site from the consensus map and used it in 3D masked classification, leading to the isolation of mature ribosomal particles (88% of consensus-refined particles). We then generated a soft-edged mask around the area of the eIF6 binding site from the consensus map as an input. Signal outside this mask was subtracted in the newly obtained mature ribosomal particles subset. We finally generated 3D classes focusing on the area inside the mask. 4 classes were obtained, of which 3 showed clear density inside the masked area indicating the unequivocal presence of eIF6 and were then pooled for quantification (83% of mature ribosomal particles).
Immunoblotting
Proteins in 1x NuPAGE LDS sample buffer (with 50 mM DTT) were incubated at 80 °C for 10 min and run on NuPAGE Bis-Tris polyacrylamide gels in NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific). The iBlot 2 gel transfer device (Thermo Fisher Scientific) was used to transfer proteins to nitrocellulose membranes. Membranes were blocked in 5 % milk in PBS supplemented with 0.1% tween (NBS Biologicals) for 1 h, and subsequently incubated with appropriate primary antibodies overnight at 4 °C on a shaker. After 3x 10 min washes with PBS-tween, the blots were incubated with the appropriate secondary horseradish peroxidase-conjugated antibody at room temperature for 1 h followed by detection using the SuperSignal West Pico PLUS reagents (Thermo Fisher Scientific). For a full list of antibodies, see Supplementary Table 2.
Subcellular fractionation
1 × 106 freshly isolated bone marrow cells from Dox-treated mice were washed twice with ice-cold PBS, and resuspended in 0.5 mL of ‘standard’ lysis buffer (20 mM Hepes pH 7.5, 50 mM KCl, 10 mM Mg(CH3COO)2, cOmplete™ EDTA-free Protease Inhibitor Cocktail, 0.5 % IGEPAL® CA-630, and 2 mM DTT. Following 30 min incubation on ice, lysates were centrifuged for 5 min at 7000 g to pellet the nuclei, while supernatants representing the cytosolic fraction were collected. Following a wash with ice-cold PBS and centrifugation as above, the nuclear pellet was resuspended in 0.5 mL of ice-cold RIPA buffer supplied with 1 U/mL Benzonase (Merck), and incubated on a rotator for 1 h at 4 °C. Following centrifugation for 5 min at 7000 g to pellet insoluble material, supernatant representing the nuclear fraction was collected. Finally, both fractions were resuspended in 1x NuPAGE LDS sample buffer with 50 mM DTT.
Quantitative real-time PCR
Total RNA was isolated from FACS-purified cells using the RNeasy mini kit (Qiagen). cDNA was transcribed with SuperScript III reverse trancriptase (Thermo Fisher Scientific). Real-time PCR reactions were performed using the SsoFast™ EvaGreen® Supermix (Bio-Rad) and ABI 7900HT fast Real-time PCR system (Thermo Fisher Scientific). Primers are listed in Supplementary Table 3.
Light microscopy
Drosophila was maintained using standard culture techniques. All crosses were performed at 25 °C. Fly strains and genotypes are described in Supplementary Tables 4 and 5. Whole Drosophila samples were collected at 1, 3, 5, and 11 days after egg laying (AEL). Larvae were fixed with 4% paraformaldehyde and adult flies were frozen before photography. For the imaging of fly eyes, two to four day old Drosophila adults were frozen at -20 °C for one hour. Both whole fly and adult eye photographs were collected using a Nikon SMZ18 microscope with NIS-Elements D (version 4.40).
Scanning Electron Microscopy
Drosophila adult eye samples were prepared as described53. Samples were viewed on a Philips XL30 scanning electron microscope.
Immunostaining
Drosophila wing discs dissected from third instar larvae in culture medium (Drosophila M3 media (Sigma), 10 % FCS (Sigma) and P/S (Sigma) were collected within 10 min into culture medium containing 50 µM of OP-Puro (Invitrogen) and kept in a 25 °C incubator for 30 min. Wing discs were then washed twice with ice-cold PBS (Invitrogen) with 1% BSA (Sigma) and 100 µg/ml CHX (Sigma). Wing discs were fixed and permeabilised using the Cytofix/Cytoperm Fixation Permeabilization Kit (BD Biosciences). Azide-alkyne cycloaddition was performed using the Click-iT Cell Reaction Buffer Kit (Invitrogen) with azide conjugated to Alexa Fluor 596 at 5 µM final concentration. Following a 30 min reaction, wing discs were washed three times in PBS and mounted on slides in medium containing DAPI (Vector). Images were collected on a Zeiss LSM710 confocal system and imported to Image J 10.4 (Image J) and Photoshop (Adobe 2020), and adjusted for brightness and contrast uniformly across entire fields.
AUTHORSHIP
Conflict-of-interest disclosure: The authors declare no competing financial interests.
ACKNOWLEDGEMENTS
This work was supported by the Swedish Childhood Cancer Fund (PDS13/001, to PJ), the Swedish Research Council (2014-06807, to PJ), a Specialist Programme from Bloodwise (12048, to AJW), the UK Medical Research Council (MC_U105161083, to AJW), a Wellcome Trust strategic award to the Cambridge Institute for Medical Research (100140, to AJW), a core support grant from the Wellcome Trust and MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, the Connor Wright Project, Ted’s Gang and the Cambridge National Institute for Health Research Biomedical Research Centre. C.C.W. acknowledges funding from a Wellcome Intermediate Fellowship (Grant Number: 105914/Z/14/Z) and the Kay Kendall Leukaemia Fund. We thank Dr. D. Y. Chirgadze for assistance with data collection at the Cryo-EM Facility, Department of Biochemistry, University of Cambridge, funded by the Wellcome Trust (206171/Z/17/Z; 202905/Z/16/Z), the Departments of Biochemistry and Chemistry, the Schools of Biological Sciences and Clinical Medicine and the University of Cambridge. We thank R. Grenfell at the Cancer Research UK Cambridge Institute for assistance with imaging flow cytometry. The Cambridge NIHR BRC Cell Phenotyping Hub supported this research. We thank T. Hamilton, D. Pask, D. Kent, G. Giotopoulos, B. Huntly and A.R. Green for facilitating animal experiments. We thank M. Freeman, the Bloomington Drosophila Stock Center, NIG-Fly Stock Center and Vienna Drosophila RNAi Center for providing fly stocks.